Clinical Research
Trials open to accrual:
An open-label phase II study evaluating the safety and efficacy of CPTK787/ZK222584 in patients with metastatic neuroendocrine tumors that have evidence of progressive disease or an increase in disease related syndrome symptoms
An open label, stratified, single-arm phase II study of RAD001 in patients with advanced pancreatic neuroendocrine tumor (NET) after failure of cytotoxic chemotherapy
A randomized, double-blind, placebo-controlled, multicenter phase III study in patients with advanced carcinoid tumor receiving Sandostatin LAR and RAD001 10 mg/d or Sandostatin LAR and placebo
Trials not yet accruing:
A phase III randomized, double-blind study of Sunitinib (SU011248, Sutent) versus placebo in patients with progressive advanced/metastatic well-differentiated pancreatic islet cell tumors
A phase I-II study evaluating the maximum tolerated dose, dosimetry, safety, and efficacy of Ultratrace Iobenguane I 131 in patients with malignant pheochromocytoma/paraganglioma
For more information on the above listed Clinical Trials, please call 504-464-8500 . For information regarding other Clinical Trials, visit http://www.clinicaltrials.gov.
Basic Science Research
Inhibition of Angiogenesis and Destruction of Angiogenic Vessels with Extracts of Noni Juice (Morinda Citrifolia). Eugene A. Woltering, M.D., Conrad A. Hornick, Ph.D., Amy E. Myers
Use of Epothilones in Hyperparathyroidism. Novartis filing patent. Eugene A. Woltering, M.D.
Inhibition of Angiogenesis and Destruction of Angiogenic Vessels with Certain Plant Extracts, Gallic Acid, and Its Derivatives. Frank Greenway, Zhijun Liu, Ph.D., Eugene A. Woltering, M.D.
Nt extract: an inhibitor of angiogenesis in humans. Frank Greenway, Zhijun Liu, Ph.D., Eugene A. Woltering, M.D.
Pomegranate extract: an inhibitor of human angiogenesis disclosure included in SN. Frank Greenway, Zhijun Liu, Ph.D., Eugene A. Woltering, M.D.
Inhibition of Angiogenesis and Destruction of Angiogenic Vessels with dogwood berry extract disclosure included in SN. Frank Greenway, Zhijun Liu, Ph.D., Eugene A. Woltering, M.D.
Inhibition of Angiogenesis and Destruction of Angiogenic Vessels with persimmon fruit calyx extract disclosure included in SN. Frank Greenway, Zhijun Liu, Ph.D., Eugene A. Woltering, M.D.
Novel Technique for Sentinel Lymph Node Mapping. Eugene A. Woltering, M.D., Yi-Zarn Wang, M.D.
Inhibition of Angiogenesis and Destruction of Angiogenic Vessels by Apolipoprotein A-I and High-Density Lipoprotein. Eugene A. Woltering, M.D. and Conrad Hornick.
Injection of a Radioactive Dye for Sentinel Lymph Node Identification. Eugene A. Woltering, M.D., Yi-Zarn Wang, M.D.
Surgical Marking Composition and Method. Eugene A. Woltering, M.D.
Human Tumor Angiogenesis Using a Fibrin-Thrombin Clot Model. Eugene A. Woltering, M.D., Andrew Heck, M.D.
Patents
U.S. Patent Number 5,590,656, Issued January 7, 1997: Application of Peptide/Cell Receptor Kinetics Utilizing Radiolabeled Somatostatin Congeners in the in situ, in vivo Detection and Differentiation of Neoplastic Tissue. Inventors: Thomas M. O’Dorisio, M.D., M. Sue O’Dorisio, M.D., Ph.D., Edward Martin, M.D., and Eugene A. Woltering, M.D.
U.S. Patent Number 5,597,894, Issued January 28, 1997: Multi-Tyrosinated Somatostatin Analogs. Inventors: David H. Coy, Ph.D., William A. Murphy, Ph.D., Eugene A. Woltering, M.D., M. Sue O’Dorisio, M.D., Ph.D., Thomas M. O’Dorisio, M.D.
U.S. Patent Number 6,180,082, Issued January 30, 2001: Method to Enhance Tissue Accumulation of Radiolabeled Compounds. Inventors: Eugene A. Woltering, M.D. and Gregory D. Espenan, M.S.
U.S. Patent Number 6,465,613, Issued October 15, 2002: Hydrophilic Somatostatin Analogs. Inventors: David H. Coy, Ph.D., William A. Murphy, Ph.D., Eugene A. Woltering, M.D., Joseph A. Fuselier, MBA, and George J. Drouant.
U.S. Patent Number 6,630,123, Issued October 7, 2003: Method to Enhance Tissue Accumulation of Radiolabeled Compounds. Inventors: Eugene A. Woltering, M.D. and Gregory D. Espenan, M.S.
U.S. Patent Number 6,893,812, Issued May 17, 2005: Three-Dimensional ex vivo Angiogenesis System. Applicants: Eugene A. Woltering, M.D. and Seza Gulec, M.D.
